Analytical Tool - Prostate Cancer (Related Reports)

Analytical Tool - Prostate Cancer


March 25, 2014
SKU: BIOS5221725
License type:
Electronic Access - Global Site License Fulfilled by Publisher      US $11,625.00
Electronic Access - Single User Fulfilled by Publisher      US $4,650.00
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
4/7/2014 | published by: Kalorama Information
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical  |  read more...
$3,995.00
Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide
4/1/2014 | published by: Renub Research
Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide Cervical Cancer Test Market Overview Cervical cancer is one of the deadliest cancers  |  read more...
$1,490.00
B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014 provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental  |  read more...
$2,500.00
Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014 provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data  |  read more...
$2,500.00
Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014 provides data on the Metastatic Breast Cancer clinical trial scenario. This report provides elemental  |  read more...
$2,500.00
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014 provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This  |  read more...
$2,500.00
Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant
4/14/2014 | published by: GBI Research
Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant Summary GBI Research, the leading business intelligence provider, has released its latest research,‘Pancreatic Adenocarcinoma  |  read more...
$3,500.00
HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth
4/14/2014 | published by: GBI Research
HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth Summary The leading business intelligence provider GBI Research has released its latest research report,  |  read more...
$3,500.00
Global Hypertension Drugs Market 2014-2018
4/4/2014 | published by: Infiniti Research Limited - TechNavio
Global Hypertension Drugs Market 2014-2018 About Hypertension Drugs Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such  |  read more...
$2,500.00
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
4/1/2014 | published by: FirstWord
Introduction Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in  |  read more...
$4,995.00